semaglutide for hypertension tirzepatide and Know the Differences Between & Tirzepatide How Semaglutide Lowers Blood Pressure

Understanding Semaglutide: What It Is: Synthetic GLP-1 receptor agonist Mimics natural GLP-1 hormone 94% identical to human GLP-1 Modifications make it last much longer in body Half-life of approximately 7 days (allows once-weekly dosing) Brand Names: Wegovy: Indication: Chronic weight management in adults with obesity or overweight with comorbidities FDA Approval: June 2021 Doses: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg (weekly) Manufacturer: Novo Nordisk Cost: $1,349/month Ozempic: Indication: Type 2 diabetes management FDA Approval: December 2017 Doses: 0.25 mg, 0.5 mg, 1.0 mg, 2.0 mg (weekly) Manufacturer: Novo Nordisk Cost: $969/month Note: Commonly prescribed off-label for weight loss Rybelsus: Indication: Type 2 diabetes management Formulation: Oral tablet (not injection) Doses: 3 mg, 7 mg, 14 mg (daily) Effectiveness: Much lower than injectable (3-5% weight loss) Not typically recommended for weight loss Compounded Semaglutide: Source: FDA-registered compounding pharmacies Indication: Prescribed for weight loss by licensed providers Doses: Custom concentrations available Cost: $199-$599/month Same active ingredient as Wegovy/Ozempic Clinical Effectiveness: STEP-1 Trial (Wegovy 2.4 mg): Duration: 68 weeks Participants: 1,961 adults with obesity Average Weight Loss: 14.9% of body weight Placebo: 2.4% weight loss 5% Weight Loss: 86.4% of participants 10% Weight Loss: 69.1% of participants 15% Weight Loss: 50.5% of participants Real-World Examples: 250-Pound Person: Average loss: 37 pounds Final weight: 213 pounds Timeline: 16-18 months 200-Pound Person: Average loss: 30 pounds Final weight: 170 pounds Timeline: 16-18 months 300-Pound Person: Average loss: 45 pounds Final weight: 255 pounds Timeline: 18-20 months Dosing Schedule: Standard Escalation: Weeks 1-4: 0.25 mg weekly (starting dose to assess tolerance) Weeks 5-8: 0.5 mg weekly Weeks 9-12: 1.0 mg weekly Weeks 13-16: 1.7 mg weekly (if tolerated) Week 17+: 2.4 mg weekly (maintenance dose for weight loss) Why Gradual Escalation: Minimizes nausea and GI side effects Allows body to adapt Identifies optimal dose for each person Some people achieve goals at lower doses Side Effects: Most Common: Nausea: 44% (usually improves after 4-8 weeks) Diarrhea: 30% Constipation: 24% Vomiting: 24% Abdominal pain: 20% Management Strategies: Eat smaller, more frequent meals Avoid fatty and spicy foods Stay well-hydrated Inject before bed (sleep through initial nausea) Anti-nausea medication if severe Slow down dose escalation if needed Discontinuation Rate: 6.9% due to side effects (relatively low) Who Should Choose Semaglutide: Ideal Candidates: Need to lose 20-50 pounds Want proven, highly effective medication Comfortable with once-weekly injections Have BMI 30 (or 27 with weight-related conditions) No contraindications to GLP-1s Can commit to long-term treatment Good for: Budget-conscious patients (compounded at $199/month) First-time GLP-1 users Those who may not need maximum potency tirzepatide Patients with cardiovascular disease (proven benefits) Cost Comparison: Advantages of Compounded Semaglutide: Cost Savings: 85% less than brand-name Wegovy $199/month makes long-term treatment affordable No insurance hassles or denials Better Availability: Not subject to same shortages as brand-name Consistent supply through compounding pharmacies Ships directly to your door in 3-7 days Telehealth Access: Complete process online No in-person doctor visits required Ongoing medical supervision included Custom Dosing: Pharmacies can prepare any concentration Allows individualized titration Flexibility in dose adjustments Access Through TrimRx : $199/month with annual commitment Licensed provider consultations included FDA-registered pharmacy partners All supplies and shipping included Monthly follow-ups with medical team Cardiovascular Benefits: SELECT Trial Results: Semaglutide showed: 20% reduction in major adverse cardiovascular events Reduced heart attacks, strokes, and cardiovascular deaths Benefits beyond weight loss alone Important for patients with heart disease history This makes semaglutide particularly valuable for patients with obesity and cardiovascular disease

Five of these trials have shown superiority in reducing MACE compared to placebo, while all have confirmed the cardiovascular safety of GLP-1 RAs (76)

For example, combining semaglutide with other GLP-1 agonists or certain diabetic medicines without medical supervision can be unsafe

What happened

None of the three compounds have human safety data in pregnancy or breastfeeding, and they are not FDA-approved

Federal regulators have flagged safety concerns about how some NAD+ compounds are sourced and made, especially injectable versions